Psychiatric disorders

News

Teva’s long-lasting schizophrenia injectable shines in Phase III

Data presented at Psych Congress 2024 showed improvements in social functioning and quality of life over an eight-week treatment period.

Jenna Philpott

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close

Sections

Sections

Sections

Sections

Sections

Teva’s long-lasting schizophrenia injectable shines in Phase III

Leading Strategic Intelligence Solutions for the Clinical Trials Industry

Key Lead Generation Providers and Technology Solutions for the Clinical Trials Industry

Sign up for our daily news round-up!

Sign up to the newsletter: In Brief

Sign up for our daily news round-up!

Sign up for our daily news round-up!

Sign up to the newsletter: In Brief

I would also like to subscribe to:

Thank you for subscribing